PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
This is a single-center, double-arm, open-label, randomized feasibility study that will determine whether a novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists, will favorably impact appropriate medication use and cardiac imaging surveillance, and will improve clinician and patient decision-making, perception, and behavior towards cardioprotective medication usage and cardiovascular disease imaging utilization.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
For this feasibility study, the researchers will create the clinical decision aid and test the central hypothesis that this novel clinical decision aid accessed via the electronic health record will be acceptable to both cancer survivors and their cardiologists and will favorably impact appropriate medication use and cardiac imaging surveillance. The hypothesis is supported by preliminary data suggesting that an initial and rudimentary version of the clinical aid increases appropriate medication use and imaging follow-up in cardio-oncology patients. Success will be determined by ≥85% of clinic visits using the clinical decision aid resulting in pursuit of medication use and cardiac imaging surveillance patterns commensurate with recommendations specific to cancer survivors, with overall rates the same or higher than the group without the clinical decision aid, as well as overall favorable patient and physician focus group comments and survey responses.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Yee Chung Cheng, MD
- Phone Number: 414-805-4600
- Email: ycheng@mcw.edu
Study Locations
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert & the Medical College of Wisconsin
-
Principal Investigator:
- Yee Chung Chen, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Cancer survivors at intermediate, high, or very high risk for developing cardiovascular disease will pursue a cardio-oncology visit.
Description
Inclusion Criteria:
- Patients ≥18 years with a history of cancer.
- Have not previously visited a cardiologist to assess cardiovascular risk after cancer diagnosis.
- Clinically at intermediate, high, or very high risk for cardiovascular diseases determined based on imprecise clinical risk models, such as those used for cardiac dysfunction.
- Ability to understand a written informed consent form, and willing to sign it prior to study registration.
Exclusion Criteria:
- Patient <18 years.
- Without a personal history of cancer.
- Existing cardiomyopathy diagnosed after cancer diagnosis.
- Documented cognitive impairment.
- Patient or patient representative who is unable and unwilling to sign the informed consent form.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Clinical Decision Aid Group
In this group, physicians will use standard care plus the clinical decision aid. |
The clinical decision aid tool will be used at the subject's first visit (Week 0), Week 12 and Week 24. |
|
Control Group
In this group, physicians will use standard care only. |
Cardiology clinic visits will take place at the subjects first visit (Week 0), Week 12 and Week 24. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Medication use
Time Frame: Week 0
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Medication use
Time Frame: Week 12
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Medication use
Time Frame: Week 24
|
The number of subjects in which medication use pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
|
Imaging surveillance
Time Frame: Week 0
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 0
|
|
Imaging surveillance
Time Frame: Week 12
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 12
|
|
Imaging surveillance
Time Frame: Week 24
|
The number of subjects in which imaging surveillance pursued is consistent with current medical society recommendations appropriate for the subject. |
Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Yee Chung Cheng, MD, Medical College of Wisconsin
Publications and helpful links
General Publications
- Brown SA, Chung BY, Doshi K, Hamid A, Pederson E, Maddula R, Hanna A, Choudhuri I, Sparapani R, Bagheri Mohamadi Pour M, Zhang J, Kothari AN, Collier P, Caraballo P, Noseworthy P, Arruda-Olson A; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity (CAIPE) Research Team Investigators. Patient similarity and other artificial intelligence machine learning algorithms in clinical decision aid for shared decision-making in the Prevention of Cardiovascular Toxicity (PACT): a feasibility trial design. Cardiooncology. 2023 Jan 23;9(1):7. doi: 10.1186/s40959-022-00151-0.
- Brown SA, Hamid A, Pederson E, Bs AH, Maddula R, Goodman R, Lamberg M, Caraballo P, Noseworthy P, Lukan O, Echefu G, Berman G, Choudhuri I; Cardio-Oncology Artificial Intelligence Informatics & Precision Equity (CAIPE) and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity (PACT) Research Team Investigators. Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology. Cardiooncology. 2023 Oct 27;9(1):37. doi: 10.1186/s40959-023-00179-w.
- Brown SA, Fang MZ, Sparapani R, Zhou Y, Osinski K, Taylor B, Yu D, Blessing J, Shah R, Collier P, BagheriMohamadiPour M, Zhang J, Kothari A, Echefu G, Rickards J, Otto C, Sanchez Z, Olson J, Arruda-Olson A, Cheng YC, Cheng F; Cardio-Oncology Artificial Intelligence Informatics and Precision Equity, and Patient Similarity Algorithms in the Prevention of Cardiovascular Toxicity Research Team Investigators. PrevCardioOncAI: Machine Learning Algorithms for Predicting Cardiovascular Disease in Cancer Survivors. J Am Heart Assoc. 2025 Dec 16;14(24):e030363. doi: 10.1161/JAHA.123.030363. Epub 2025 Dec 11.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Wounds and Injuries
- Pathologic Processes
- Heart Diseases
- Metabolic Diseases
- Glucose Metabolism Disorders
- Chemically-Induced Disorders
- Drug-Related Side Effects and Adverse Reactions
- Radiation Injuries
- Atherosclerosis
- Arteriosclerosis
- Arterial Occlusive Diseases
- Peripheral Vascular Diseases
- Coronary Disease
- Myocardial Ischemia
- Pathological Conditions, Signs and Symptoms
- Nutritional and Metabolic Diseases
- Neoplasms
- Heart Failure
- Hypertension
- Ischemia
- Diabetes Mellitus
- Cardiomyopathies
- Peripheral Arterial Disease
- Coronary Artery Disease
- Cardiotoxicity
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
Other Study ID Numbers
- PRO00039290
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.